{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'may be used so long as it is performed within 28 days prior to randomization. All subjects', 'will have a bone scan (scintigraphy) performed at screening/baseline. Subjects with positive', 'bone scans at baseline will have a bone scan performed every 56 days ( 7 days) throughout', 'the study or more frequently if clinically indicated. Subjects should have a follow-up bone', 'scan performed if clinically indicated regardless of baseline status. Brain scans (computed', 'tomography [CT] with contrast/magnetic resonance imaging [MRI]) will only be performed', 'if clinically indicated at screening/baseline and repeated as clinically indicated or per', 'standard of care throughout the study.', 'QOL assessments and PRO will be collected at protocol-specified time points from all', 'randomized subjects. The following validated tools will be used: European Organisation for', 'Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) and', 'EuroQOL 5-dimension 5-Level Questionnaire (EQ-5D-5L). HRU information will be', 'collected at protocol-specified time points with particular focus on the number of subjects', 'who have an unplanned use of healthcare resources related to clinical or AEs from subjects', 'assigned to treatment arms A and B.', 'Blood samples for pharmacokinetics and ATA will be collected throughout the study for', 'subjects randomized into Arm A. Validated assays will be used to measure the concentrations', 'of EV ADC and monomethylauristatin E (MMAE) in serum or plasma and to assess ATA.', 'Pharmacokinetic samples will not be collected from subjects randomized into Arm B.', 'Samples for exploratory biomarkers will be collected at protocol-specified time points.', 'Biomarker assessments will not be used for subject selection.', 'Following discontinuation from study drug, subjects will have a follow-up visit 30 days', '(+ 7 days) after their last dose of drug for safety assessments. If a subject discontinues study', 'drug prior to radiographic disease progression (i.e., PFS1), the subject should enter the post-', 'treatment follow-up period and continue to undergo imaging assessments every 56 days', '( 7 days) until PFS1 is documented, or the subject starts another anticancer treatment,', 'whichever occurs earlier.', 'Following PFS1, subjects will enter the long-term follow-up period and be followed per', 'institutional guidelines but not less than every 3 months from the date of the follow-up visit', 'for survival status and progression status on subsequent therapy (i.e., PFS2).', 'Subjects will be followed until PFS2 is documented or the subject starts another anticancer', 'treatment, whichever occurs earlier. All subsequent anticancer therapy including date and site', 'of progression for PFS2 will be recorded on the case report form.', 'Following PFS2, subjects will enter the survival follow-up period and be followed every', '3 months for survival status until death, lost to follow-up, withdrawal of study consent, or', 'study termination by sponsor. This study is expected to end once final survival analysis is', 'complete. Subjects will be eligible to continue receiving treatment in this study until they', 'meet a discontinuation criterion as outlined in [Section 6 Discontinuation or upon', 'study', 'termination, or study completion, whichever occurs first.', '14 Sep 2020', 'Astellas', 'Page 45 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'An IDMC will be chartered to oversee safety and the planned interim efficacy analysis,', 'which will occur after at least 285 OS events (about 65% of the total planned events) are', 'observed. The primary analysis will occur at 439 os events. The IDMC may recommend to', 'the sponsor whether the trial should be terminated, modified or continue unchanged based on', 'ongoing reviews of safety data and interim efficacy analysis. Further details will be outlined', 'in the IDMC charter.', '2.2.2 Dose Rationale', 'Enfortumab Vedotin', 'EV will be administered at a dose of 1.25 mg/kg as an intravenous infusion over', 'approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle. This dose and regimen', 'has demonstrated an acceptable safety profile and encouraging clinical activity in the phase 1', 'study [Study ASG-22CE-13-2], which evaluated escalating dose levels of 0.5, 0.75, 1 and', '1.25 mg/kg, with expansion cohorts at the 0.75, 1, and 1.25 mg/kg dose levels. A maximum', 'tolerated dose (MTD) was not reached in this study. At the 1 mg/kg dose level, 2 dose-', 'limiting toxicities (DLTs) were observed: Grade 3 proctalgia (later changed to grade 2 by the', 'investigator) thought related to radiation recall and Grade 4 hyperuricemia without clinical', 'sequelae. No DLT was observed at 1.25 mg/kg and doses above 1.25 mg/kg were not tested.', 'Incidence of some of the most frequent drug-related AEs, such as diarrhea and rash, although', 'primarily Grades 1-2 and clinically manageable, increased with increasing dose levels.', 'Moreover, dose reductions due to AEs were more frequent for the 1.25 mg/kg VS lower dose', 'levels. Safety assessments of both metastatic urothelial cancer patients and non-metastatic', 'urothelial cancer patients showed that frequency of all TEAEs, AEs leading to withdrawal,', 'and Grade 3-4 TEAEs were comparable across all dose levels.', 'While all doses of EV demonstrated activity, the 1.25 mg/kg dose was associated with the', 'highest activity and had an acceptable safety profile.', 'Based on pharmacokinetic data from the phase 1 study [Study ASG-22CE-13-2], the half-life', 'of EV is ~ 1 - 2 days. No notable <30%) intra-cycle accumulation of ADC was observed', 'with the current dosing regimen (on Days 1, 8 and 15 of every 28-day cycle) at any dose', 'level. Minimal (< 50%) intra-cycle accumulation of MMAE was observed. It is anticipated', 'that the dosing schedule in the study will maintain ADC exposures over each 28-day cycle,', 'contributing to a favorable balance of activity and safety, as observed in the phase 1 trial', '[Study ASG-22CE-13-2].', 'In summary, the dose regimen of 1.25 mg/kg on Days 1, 8 and 15 of each 28-day cycle', 'proposed for this study has demonstrated an acceptable safety profile and encouraging', 'clinical activity that was higher than at lower dose levels.', 'Comparators', 'There is no accepted standard of care following CPI treatment for locally advanced or mUC;', 'however, prior to CPI approvals, taxanes were commonly used following platinum-based', 'therapy as recommended in the treatment guidelines [NCCN, 2017; ESMO, 2017]. In', '14 Sep 2020', 'Astellas', 'Page 46 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}